# Can GLP-1 Weight Loss Drugs Give Athletes an Unfair Advantage?
GLP-1 receptor agonists like semaglutide and tirzepatide have sparked debate among sports regulators about whether these drugs create unfair competitive advantages. Athletes use these medications to shed pounds and improve performance metrics, raising questions about fair play in professional and amateur sports.
The drugs work by slowing gastric emptying and increasing feelings of fullness, which reduces calorie intake. For athletes in weight-class sports like boxing, wrestling, and rowing, rapid weight loss before competition becomes tempting. Some athletes report losing 10 to 15 pounds in weeks, potentially allowing them to compete in lower weight classes against smaller opponents.
Sports governing bodies have begun responding. The World Anti-Doping Agency (WADA) added semaglutide and tirzepatide to its monitoring list in 2024, though they remain legal for therapeutic use. Individual sports organizations have started crafting their own policies. Some have banned the drugs outright for competition, while others require medical exemptions to confirm legitimate treatment for diabetes or obesity.
The competitive edge cuts multiple ways. Beyond weight loss, GLP-1 drugs may improve body composition by preserving muscle while reducing fat, potentially enhancing strength-to-weight ratios. Athletes also report better energy levels and reduced hunger during training, though scientific data on these effects remains limited in athletic populations.
Medical experts stress that GLP-1 drugs carry real risks, including pancreatitis, thyroid concerns, and muscle loss when used improperly for weight loss in non-diabetic athletes. The medications were designed for people with type 2 diabetes or obesity, not for athletic enhancement.
Natasha Pitt, an anti-doping expert, emphasized that using these drugs for performance gain without medical justification violates the